Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Gabriele MulthoffSophie SeierStefan StanglWolfgang SievertMaxim ShevtsovCaroline WernerAlan Graham PockleyChristiane BlankensteinMartin HildebrandtRobert OffnerNorbert AhrensKonrad KokowskiMatthias G HautmannClaus RödelRainer FietkauDorota LubganRudolf Maria HuberThomas DuellMichael MollsHanno SpechtBernhard HallerMichal DeveckaAndreas Philipp SauterStephanie E CombsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Ex vivo TKD/IL2-activated, autologous NK cells are well tolerated and deliver positive clinical responses in patients with advanced NSCLC after RCT.